Treatment

Dr. Price, APS Board member, and Dr. Mogil, Narcessian award recipient, discuss differences in biological pain pathways between men and women and the pain-relieving drugs used to treat them.

After many years and a burgeoning opioid prescription and abuse crisis, it’s still not clear whether opioids are truly effective for managing long term non-cancer pain conditions.

This article reviews historical and recent changes in the management of pediatric pain, especially after surgery.

This webinar will introduce the audience to several funding opportunity announcements (FOAs), all seeking to develop medical devices to treat pain.

The FDA recently approved a powerful new opioid with higher potency than fentanyl.

Patients at Akron General in Ohio hospital are getting non-opioid drugs to manage pain before and after operations.

Today, the U.S. Food and Drug Administration took new steps as part of its broader efforts to address the opioid crisis by approving the final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS).

Canadian researchers publish important findings about fibromyalgia patients participating in online acceptance commitment therapy in The Journal of Pain.

Illinois recently legalized medical cannabis as a substitute for prescription pain killers. APS Director-at-Large, Dr. Mark Wallace, adds his research and experience to the discussion.

Are you seeking to advance your skills in pain management or palliative care, or do you know of a colleague who is? The ASHP Foundation is now accepting applications for the Advanced Pain Management and Palliative Care Traineeship.

APS President Dr. William Maixner and APS Board Member Dr. John Markman speak to NPR on how to talk to your doctor about pain.

A recent study found that patients who were educated on the neuroscience of pain and persisted in challenging physical therapy despite their chronic pain had better mental and physical health, and less disability than the standard treatment. The researchers conclude that staying active despite the pain can result in overall better health – including the pain itself.

APS Director-at-Large, Dr. Mark Wallace, appears in an article that reports on the positive impact of medical marijuana use among seniors.

New research, published this month by the American Pain Society (APS), adds to burgeoning scientific evidence showing that interdisciplinary pain rehabilitation programs are an effective alternative to opioids for chronic pain management.

As part of the agency's ongoing commitment to address the epidemic of opioid misuse and abuse, the U.S. Food and Drug Administration today launched an innovation challenge to spur the development of medical devices, including digital health technologies and diagnostic tests that could provide novel solutions to detecting, treating and preventing addiction, addressing diversion and treating pain.

APS Urges Expanded Insurance Coverage for Interdisciplinary Pain Care

On May 30-31, 2018, the inaugural meeting of the Pain Management Task Force will feature speakers from HHS, VA, DoD, ONDCP as well as perspectives on pain management from experts in the field.

APS Director-at-Large, Dr. Mark Wallace, appears in a CNN special that explores treating patients with medical marijuana and how it can help solve or ease the opioid epidemic. In the special Dr. Sanjay Gupta interviews a patient of Wallace’s who was diagnosed with an inflammation of the spine.

The NINDS Innovation Grants to Nurture Initial Translational Efforts (IGNITE) and Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program will be having a webinar on April 16, 2018 from 1:30-2:30 pm EST to inform applicants about an area of special interest. NINDS would like to accelerate the development of pain treatments with little or no potential for misuse or addiction.

The 2018 National Rx Drug Abuse and Heroin Summit, National Institutes of Health Director Francis S. Collins, MD, PhD, announced the launch of the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.